X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. ( XFOR ) is a biopharmaceutical firm built around its main asset, called Mavorixafor. The treatment is commercially branded as Xolremdi, and it's approved in the US for WHIM syndrome. It's also in the process of expanding toMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busine ...